Novel therapies and approaches to relapsed/refractory HL beyond chemotherapy

Alain Antoine Mina, Chetan Vakkalagadda, Barbara Pro*

*Corresponding author for this work

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Although Hodgkin lymphoma (HL) is highly curable with first-line therapy, relapses occur in approximately 10–20% of patients with early stage disease and 30–40% of patients with advanced stage disease. The standard approach for relapsed or refractory disease is salvage therapy, followed by consolidation with high dose therapy and autologous stem cell transplant (ASCT). Patients who achieve a complete response to salvage therapy prior to ASCT have better outcomes, thus recent studies have focused on incorporating newer agents in this setting. Major challenges in the management of relapsed patients remain how to choose and sequence the many salvage therapies that are currently available and how to best incorporate novel agents in the current treatment paradigms. In this article, we will summarize the most recent advances in the management of patients with recurrent HL and will mainly focus on the role of new agents approved and under investigation. Aside from brentuximab vedotin and checkpoint inhibitors, other novel agents and therapies are showing promising early results. However, at least with some of the newest targeted strategies, it is important to recognize that we are facing new challenges in terms of toxicities, which require very close monitoring and education of both the patient and treating physician.

Original languageEnglish (US)
Article number421
JournalCancers
Volume11
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Hodgkin Disease
Salvage Therapy
Drug Therapy
Stem Cells
Transplants
Therapeutics
Patient Education
Physicians
Recurrence

Keywords

  • Classical Hodgkin lymphoma
  • Refractory disease
  • Relapsed disease
  • Salvage therapy
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mina, Alain Antoine ; Vakkalagadda, Chetan ; Pro, Barbara. / Novel therapies and approaches to relapsed/refractory HL beyond chemotherapy. In: Cancers. 2019 ; Vol. 11, No. 3.
@article{6fa998b73c594442b31c1b3e16a72201,
title = "Novel therapies and approaches to relapsed/refractory HL beyond chemotherapy",
abstract = "Although Hodgkin lymphoma (HL) is highly curable with first-line therapy, relapses occur in approximately 10–20{\%} of patients with early stage disease and 30–40{\%} of patients with advanced stage disease. The standard approach for relapsed or refractory disease is salvage therapy, followed by consolidation with high dose therapy and autologous stem cell transplant (ASCT). Patients who achieve a complete response to salvage therapy prior to ASCT have better outcomes, thus recent studies have focused on incorporating newer agents in this setting. Major challenges in the management of relapsed patients remain how to choose and sequence the many salvage therapies that are currently available and how to best incorporate novel agents in the current treatment paradigms. In this article, we will summarize the most recent advances in the management of patients with recurrent HL and will mainly focus on the role of new agents approved and under investigation. Aside from brentuximab vedotin and checkpoint inhibitors, other novel agents and therapies are showing promising early results. However, at least with some of the newest targeted strategies, it is important to recognize that we are facing new challenges in terms of toxicities, which require very close monitoring and education of both the patient and treating physician.",
keywords = "Classical Hodgkin lymphoma, Refractory disease, Relapsed disease, Salvage therapy, Targeted therapy",
author = "Mina, {Alain Antoine} and Chetan Vakkalagadda and Barbara Pro",
year = "2019",
month = "3",
day = "1",
doi = "10.3390/cancers11030421",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

Novel therapies and approaches to relapsed/refractory HL beyond chemotherapy. / Mina, Alain Antoine; Vakkalagadda, Chetan; Pro, Barbara.

In: Cancers, Vol. 11, No. 3, 421, 01.03.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Novel therapies and approaches to relapsed/refractory HL beyond chemotherapy

AU - Mina, Alain Antoine

AU - Vakkalagadda, Chetan

AU - Pro, Barbara

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Although Hodgkin lymphoma (HL) is highly curable with first-line therapy, relapses occur in approximately 10–20% of patients with early stage disease and 30–40% of patients with advanced stage disease. The standard approach for relapsed or refractory disease is salvage therapy, followed by consolidation with high dose therapy and autologous stem cell transplant (ASCT). Patients who achieve a complete response to salvage therapy prior to ASCT have better outcomes, thus recent studies have focused on incorporating newer agents in this setting. Major challenges in the management of relapsed patients remain how to choose and sequence the many salvage therapies that are currently available and how to best incorporate novel agents in the current treatment paradigms. In this article, we will summarize the most recent advances in the management of patients with recurrent HL and will mainly focus on the role of new agents approved and under investigation. Aside from brentuximab vedotin and checkpoint inhibitors, other novel agents and therapies are showing promising early results. However, at least with some of the newest targeted strategies, it is important to recognize that we are facing new challenges in terms of toxicities, which require very close monitoring and education of both the patient and treating physician.

AB - Although Hodgkin lymphoma (HL) is highly curable with first-line therapy, relapses occur in approximately 10–20% of patients with early stage disease and 30–40% of patients with advanced stage disease. The standard approach for relapsed or refractory disease is salvage therapy, followed by consolidation with high dose therapy and autologous stem cell transplant (ASCT). Patients who achieve a complete response to salvage therapy prior to ASCT have better outcomes, thus recent studies have focused on incorporating newer agents in this setting. Major challenges in the management of relapsed patients remain how to choose and sequence the many salvage therapies that are currently available and how to best incorporate novel agents in the current treatment paradigms. In this article, we will summarize the most recent advances in the management of patients with recurrent HL and will mainly focus on the role of new agents approved and under investigation. Aside from brentuximab vedotin and checkpoint inhibitors, other novel agents and therapies are showing promising early results. However, at least with some of the newest targeted strategies, it is important to recognize that we are facing new challenges in terms of toxicities, which require very close monitoring and education of both the patient and treating physician.

KW - Classical Hodgkin lymphoma

KW - Refractory disease

KW - Relapsed disease

KW - Salvage therapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85064349651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064349651&partnerID=8YFLogxK

U2 - 10.3390/cancers11030421

DO - 10.3390/cancers11030421

M3 - Review article

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 3

M1 - 421

ER -